Skripsi
PERBEDAAN ABSOLUTE LYMPHOCYTE COUNT SEBELUM DAN SESUDAH PEMBERIAN TERAPI SIKLOFOSFAMID PADA PASIEN LUPUS ERITEMATOSUS SISTEMIK ANAK
Backgroud: Systemic Lupus Eritematosus (SLE) is an autoimmune condition that affects multiple organs and often induced periods of remission and relapse. One of the therapies used is cyclophosphamide. However, previous studies have shown that cyclophosphamide has side effects, including lymphopenia. Methods: This studies is an analitic observational study with a cross sectional study design. Data were taken from the medical record of pediatric SLE patients who received cyclophosphamide therapy at Dr. Mohammd Hoesin General Hospital Palembang, from January 2020 to October 2024. The sample for this study consisted 50 samples. Sampling was taken using the total sampling method. The data were processed using SPSS 27 version and analyzed with wilcoxon test. Results: In this study, there were 50 research samples. Female patients dominated the sample, with 44 participants being female. The age range of patients was between 6 and 17 years old, with a mean age of 13.4 ± 2.807 years. The mean Absolute Lymphocyte Count (ALC) before therapy was 1,557.54 cells/mm3 and after therapy, it was 1,347.58 cells/mm3. There was an increase in the number of patients with lymphopenia due to cyclophosphamide administration, and a decreased in the mean Absolute Lymphocyte Count (ALC) before and after therapy during the three-months observation period, but it was not statistically significant. Conclusion: There was no significant difference in ALC; however, a decrease in the median ALC was observed before and after three months of cyclophosphamide therapy in pediatric SLE patients at Dr. Mohammad Hoesin General Hospital, Palembang, during the period of January 2020 to October 2024.
| Inventory Code | Barcode | Call Number | Location | Status |
|---|---|---|---|---|
| 2407006827 | T161290 | T1612902024 | Central Library (REFERENCE) | Available but not for loan - Not for Loan |
No other version available